Poly-de-prescribing to treat polypharmacy: efficacy and safety

Therapeutic Advances in Drug Safety

Volumn 9, Issue 1, 2018, Pages 25-43

  Garfinkel, Doron ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b Israel Cancer Association   (Israel)

Author keywords

de prescribing; dementia; frailty; geriatric palliative; inappropriate medication use; polypharmacy; quality of life

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIALLERGIC AGENT; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; ERYTHROPOIETIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAXATIVE; METFORMIN; MIRTAZAPINE; NEW DRUG; NITRIC ACID DERIVATIVE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT; SULFONYLUREA; THYROXINE; UNINDEXED DRUG; WARFARIN;

AGED; APPETITE; ARTICLE; CLINICAL OUTCOME; COGNITION; COMPLICATION; CONTROLLED STUDY; DEMENTIA; DEPRESCRIPTION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FAMILY STUDY; FEMALE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENERAL PRACTITIONER; GERIATRIC ASSESSMENT; HOME CARE; HOSPITALIZATION; HUMAN; INCONTINENCE; ISRAEL; LIKERT SCALE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SLEEP PARAMETERS; SLEEP QUALITY; SYMPTOM;

EID: 85039757173     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098617736192     Document Type: Article

References (79)

1. Garfinkel D, Ilhan B, Bahat G., Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf 2015; 6: 212–233.
2. Garfinkel D., Overview of Current and future research and clinical directions for drug discontinuation - psychological, traditional and professional obstacles to de-prescribing. Eur J Hosp Pharm 2017; 24: 16–20.
3. Park HY, Park JW, Song HJ. The association between polypharmacy and dementia: a nested case-control study based on a 12-year longitudinal cohort database in South Korea. PLoS One 2017; 12: e0169463.
4. Gnjidic D, Hilmer SN, Blyth FM. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65: 989–995.
5. Viktil KK, Blix HS, Moger TA. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Brit J Clin Pharmacol 2007; 63: 187–195.
6. Onder G, Pedone C, Landi F. Adverse drug reactions as cause of hospital admissions: results from the Italian group of pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50: 1962–1968.
7. Lau DT, Mercaldo ND, Harris AT. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord 2010; 24: 56–63.
8. Garfinkel D, Zur-Gil S, Ben-Israel J., The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 2007; 9: 430–434.
9. Garfinkel D, Mangin D., Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170: 1648–1654.
10. James PA, Oparil S, Carter BL. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014; 311: 507–520.
11. Larson EB., Evidence, guidelines, performance incentives, complexity, and old people: clinician’s dilemma. J Am Geriatr Soc 2009; 57: 353–354.
12. Arguedas JA, Perez MI, Wright JM., Treatment blood pressure targets for hypertension. Cochrane Database Sys Rev 2009; 8: CD004349.
13. Molander L, Lovheim H, Norman T. Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc 2008; 56: 1853–1859.
14. Ungar A, Pepe G, Lambertucci L. Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc 2009; 57: 291–296.
15. Fried LP, Tangen CM, Walston J. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M156.
16. Maher RL, Hanlon J, and Hajja ER., Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57–65.
17. Ernst FR, Grizzle AJ., Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41: 192–199.
18. Bootman JL, Harrison DL, Cox E., The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–2096.
19. Hilmer SN, Gnjidic D., The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85: 86–88.
20. Jyrkka J, Enlund H, Lavikainen P. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011; 20: 514–522.
21. Anderson K, Stowasser D, Freeman C. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014; 4: e006544.
22. Reeve E, To J, Hendrix I. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013; 30: 793–807.
23. Schuling J, Gebben H, Veehof LJ. De-prescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012; 13: 56.
24. Ostini R, Hegney D, Jackson C. Knowing how to stop: ceasing prescribing when the medicine is no longer required. J Manag Care Pharm 2012; 18: 68–72.
25. Reeve E, Gnjidic D, Long J. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol 2015; 80: 1254–1268.
26. Reeve E, Denig P, Hilmer S. The ethics of deprescribing in older adults. J Bioeth Inq 2016; 13: 581–590.
27. McKean M, Pillans P, Scott IA., A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern Med J 2016; 46: 35–42.
28. Scott IA, Anderson K, Freeman C., Evidence-based deprescribing: reversing the tide of potentially inappropriate polypharmacy. J Clin Outc Manag 2016; 23: 359–369.
29. van der Cammen TJ, Rajkumar C, Onder G. Drug cessation in complex older adults: time for action. Age Ageing 2014; 43: 20–25.
30. Nobili A, Marengoni A, Tettamanti M. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 2011; 6: 597–602.
31. de Souto Barreto P, Ferrandez AM, Saliba-Serre B. Are older adults who volunteer to participate in an exercise study fitter and healthier than nonvolunteers? The participation bias of the study population. J Phys Act Health 2013; 10: 359–367.
32. Golomb BA, Chan VT, Evans MA. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open 2012; 2: e000833.
33. Kaiser C, Jeger R, Wyrsch S.; TIME Investigators. Selection bias of elderly patients with chronic angina referred for catheterization. Int J Cardiol 2006; 110: 80–85.
34. Sugisawa H, Kishino H, Sugihara Y. Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly. Nippon Koshu Eisei Zasshi 2000; 47: 337–349. Japanese.
35. Boyd CM, Darer J, Boult C. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716–724.
36. Gillam SJ, Siriwardena N, Steel N., Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework: a systematic review. Ann Fam Med 2012; 10: 461–468.
37. Tinetti ME, Bogardus ST, Jr Agostini JV., Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Eng J Med 2004; 351: 2870–2874.
38. Tinetti ME, Fried T., The end of the disease era. Am J Med 2004; 116: 179–185.
39. Mangin D, Heath I., Multimorbidity and quaternary prevention (P4). Rev Bras Med Fam Comunidade 2015; 10: 1–5.
40. Rochon PA, Gurwitz JH., Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315: 1096–1099.
41. Gill SS, Mamdani M, Naglie G. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165: 808–813.
42. Carter SM, Rogers W, Heath I. The challenge of over-diagnosis begins with its definition. BMJ 2015; 350: h869.
43. Angell M., The truth about drug companies: how they deceive us and what to do about it. New York, NY: The Random House Publishing Group, Inc.; 2005.
44. Gotzsche P., Deadly medicines and organized crime - How big pharma has corrupted healthcare. London, UK: Radcliffe Medical Press; 2013.
45. Healy D, Cattel D., Interface between authorship, industry and science in the domain of therapeutics. Brit J Psychiatry 2003; 183: 22–27.
46. Healy D., Pharmageddon. Berkeley, CA: University of California Press; 2012.
47. Moynihan R, Doust J, Henry D., Preventing over-diagnosis: how to stop harming the healthy. BMJ 2012; 344: e3502.
48. Moynihan R, Glasziou P, Woloshin S. Winding back the harms of too much medicine. BMJ 2013; 346: f1271.
49. Choudhry NK, Stelfox HT, Detsky AS., Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612–617.
50. American Geriatrics Society 2015 Updated Beers Criteria Expert panel. American geriatrics society 2015 updated Beer criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63: 2227–2246.
51. O’Mahony D, O’Sullivan D, Byrne S. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015; 44: 213–218.
52. Wehling M, Burkhardt H, Kuhn-Thiel A. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 2016; 45: 262–267.
53. Rognstad S, Brekke M, Fetveit A. The Norwegian general practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care 2009; 27: 153–159.
54. Rudolph JL, Salow MJ, Angelini MC. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508–513.
55. Hilmer SN, Mager DE, Simonsick EM.; Health ABC Study. Drug burden index score and functional decline in older people. Am J Med 2009; 122: 1142–1149, e1–2.
56. Chang CB, Chan DC., Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging 2010; 27: 947–957.
57. Steinman MA, Rosenthal GE, Landefeld CS. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med 2009; 169: 1326–1332.
58. Hanlon JT, Schmader KE., The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging 2013; 30: 893–900.
59. Haque R., ARMOR: a tool to evaluate polypharmacy in elderly persons. Ann Long Term Care [Internet]. 2009; 17: 26–30.
60. Mallery LH, Ransom T, Steeves B. Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program. J Am Med Dir Assoc 2013; 14: 801–808.
61. Moorhouse P, Mallery LH., Palliative and therapeutic harmonization: a model for appropriate decision-making in frail older adults. J Am Geriatr Society 2012; 60: 2326–2332.
62. Scott IA, Gray LC, Martin JH. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med 2012; 125: 529–537.
63. Holmes HM, Hayley DC, Alexander GC. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166: 605–609.
64. Cohen S., The concentration and persistence in the level of health expenditures over time: estimates for the U.S. population, 2012–2013. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Statistical Brief #481.
65. Hogan C, Lunney J, Gabel J. Medicare beneficiaries’ costs of care in the last year of life. Health Aff (Millwood) 2001; 20: 188–195.
66. Lubitz JD, Riley GF. Trends in medicare payments in the last year of life. N Eng J Med 1993; 328: 1092–1096.
67. Institute of Medicine. Living well with chronic illness. Washington, DC: National Academies Press; 2012.
68. Mangin D, Heath I, Jamoulle M., Beyond diagnosis: rising to the multimorbidity challenge (editorial). BMJ 2012; 344: e3526.
69. Scott IA, Hilmer SN, Reeve E. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175: 827–834.
70. Sengstock D, Zimmerman J, Williams B. 53. Addressing polypharmacy improving medication adherence; section IV: common clinical scenarios in geriatrics. In: Current diagnosis and treatment: geriatrics. 2nd ed. McGraw-Hill, 2 Pennsylvania Plaza New York City / Medical; 2014, p. 608.
71. Campins L, Serra-Prat M, Gózalo I.; REMEI Group. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Prac 2016; 34: 36–42.
72. Scott IA, Anderson K, Freeman CR. First do no harm: a real need to deprescribe in older patients. Med J Aust 2014; 201: 390–392.
73. Greenhalgh T, Howick J, Maskrey N., Evidence based medicine: a movement in crisis? BMJ 2014; 348: g3725.
74. Sackett DL, Rosenberg WM, Gray JA. Evidence based medicine: what it is and what it isn’t. BMJ 1996; 312: 71–72.
75. Reeve E, Turner JP., Patients’ perspectives on the brave new word ‘de-prescribing’. Int Pharm Prac 2015; 23: 90–91.
76. Linsky A, Simon SR, Bokhour B., Patient perceptions of proactive medication discontinuation. Patient Educ Couns 2015; 98: 220–225.
77. Reeve E, Low LF, Hilmer SN., Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. Br J Gen Pract 2016; 66: e552–e560.
78. Sirois C, Ouellet N, Reeve E., Community-dwelling older people’s attitudes towards deprescribing in Canada. Res Social Admin Pharmacy 2017;13: 864–870.
79. Garfinkel D., The tsunami in 21st century healthcare: the age-related vicious circle of co-morbidity. J Nutr Health Aging 2013; 17(Suppl. 1): SS24, 227–C1, S96–97.